Last reviewed · How we verify
Rubidium Bromatum (RUBIDIUM)
At a glance
| Generic name | RUBIDIUM |
|---|---|
| Sponsor | Jubilant |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2016 |
Approved indications
- Positron emission tomography
Common side effects
Key clinical trials
- Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma (PHASE2)
- Parathyroid Adenoma Detection With Rubidium-82 Imaging
- Assessment of Renal Microcirculation With Rubidium Positron Emission Tomography
- A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers (NA)
- A Pilot Study Evaluating the Potential of 18F Fluorodeoxyglucose PET-CT Imaging in Diagnosing Cardiac Rejection. (NA)
- Dose Optimization for Rubidium PET Imaging in Patients With Known or Suspected Ischemic Heart Disease
- Assessment of Coronary Artery Disease by Hybrid PET/CT (NA)
- CO2 as a Stress Agent for Perfusion Imaging (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |